Skip to content
ppharmaranks
Menu
Class IIIOngoing

Glycopyrrolate Oral Solution recall

FDA recall D-0300-2026 · initiated Dec 15, 2025

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Feb 4, 2026How we research

NOVADOZ PHARMACEUTICALS LLC recalled Glycopyrrolate Oral Solution in Dec 2025 — an FDA Class III recall (D-0300-2026) because Failed Impurities/Degradation Specifications.

Unlikely to cause harm but violates FDA labeling or manufacturing regulations.

Why it was recalled

Failed Impurities/Degradation Specifications

An impurity above the accepted limit

A by-product of manufacturing or storage exceeded the limit the FDA accepts. Nitrosamines are the common example: the concern is long-term exposure, not immediate danger from one dose.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot # CB2505159A, CB2505160A, Exp Date: 04/2027; Lot # CB2505161A, Exp Date: 05/2027

Quantity recalled: N/A

Details

Product
Glycopyrrolate Oral Solution, 1 mg/5 mL, 16 oz. (473 mL), Rx only, Manufactured by: MSN Pharmaceuticals Inc., Piscataway, NJ 08854, Distributed by: Novadoz Pharmaceuticals LLC, Piscataway, NJ 08854, NDC 72205-070-72
Recalling company
NOVADOZ PHARMACEUTICALS LLC
Classification
Class III
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
US Nationwide.
Initiated
Dec 15, 2025
FDA report date
Feb 4, 2026
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Glycopyrrolate Oral Solution recalled?
NOVADOZ PHARMACEUTICALS LLC recalled Glycopyrrolate Oral Solution in Dec 2025 — an FDA Class III recall (D-0300-2026) because Failed Impurities/Degradation Specifications. Unlikely to cause harm but violates FDA labeling or manufacturing regulations.
Why was Glycopyrrolate Oral Solution recalled?
Per the FDA enforcement record, the reason for recall D-0300-2026 was: Failed Impurities/Degradation Specifications
Is a recalled Glycopyrrolate Oral Solution dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. Unlikely to cause harm but violates FDA labeling or manufacturing regulations. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Glycopyrrolate Oral Solution are affected?
Distributed: US Nationwide.. The recall covers these lots — Lot # CB2505159A, CB2505160A, Exp Date: 04/2027; Lot # CB2505161A, Exp Date: 05/2027. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0300-2026.

Source: openFDA Drug Enforcement record D-0300-2026

← All drug recalls